Rudolph Castellani
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Year:
2026
Year:
2026
Year:
2025
Introduction: There are no validated clinical diagnostic criteria for chronic traumatic encephalopathy or traumatic encephalopathy syndrome (TES). To understand the historical clinical condition, its applicability to modern day athletes, and the pathogenesis of clinical problems, we examined the literature describing boxers from the 20th century, with specific attention paid to neurological findings and characteristics of clinical disease progression. Methods: Data were extracted for 243 boxers included in 45 articles published between 1928 and 1999, including cases from articles originally published in German. The presence or absence of 22 neurological signs and features were extracted. Results: The most common neurological problems were slurring dysarthria (49%), gait disturbances (44%), and memory loss (36%), with several other problems that were less frequent, including hyperreflexia (25%), ataxia (22%), increased tone (19%), and extensor Babinski sign (16%). Frank dementia appeared in some cases (17%). There were significantly fewer neurological deficits reported in boxers who fought in the latter part of the 20th century compared to boxers who fought earlier in the century. For more than half of the cases, there were no comments about whether the neurological problems were progressive (145, 60%). A progressive condition was described in 71 cases (29%) and a stationary or improving condition was described in 27 cases (11%). Canonical neurodegenerative disease-like progression was described in 15 cases (6%). Discussion: Neurological problems associated with boxing-related neurotrauma during the 20th century are the foundation for present-day TES. However, the clinical signs and features in the 20th century differ in most ways from the modern criteria for TES.
Year:
2025
Year:
2025
Background Researchers have reported that hyperphosphorylated tau (p-tau) accumulates in the Cornu Ammonis 2 subfield (CA2) of the hippocampus with age, preferentially in primary age-related tau astrogliopathy, in association with early Alzheimer's disease, and preferentially in chronic traumatic encephalopathy neuropathologic change. Objective Examine the possible association between preferential p-tau in the CA2 region of the hippocampus and history of playing high school American-style football. Methods Postmortem brain tissue samples were obtained from the Lieber Institute for Brain Development for 174 men (median age at death = 65 years; range = 50–96). There were 126 with no known history of participation in contact or collision sports and 48 (27.6%) who participated in football. Results Approximately half were rated modified Braak stage I (47.1%) and modified CERAD stage 0 (52.0%). Preferential CA2 p-tau was present in 29.9%. The average age for those with versus without preferential CA2 p-tau was 75 and 63, respectively (Cohen's d = −1.27, large effect). The sport history groups did not differ in age (p = 0.607). In both univariate and multivariate logistic regressions, older age groups (odds ratio [OR] = 3.42 and 3.23) and those with greater modified CERAD scores (OR = 1.78 and 1.48) were significantly more likely to have preferential CA2 p-tau. There was not a significant association between football participation and preferential CA2 p-tau. Conclusions There was not a significant association between participation in high school football and preferential CA2 p-tau identified after death. These results support other theories in the literature—that preferential CA2 p-tau is associated with aging and with Alzheimer's disease neuropathologic change.
Year:
2025
The Alzheimer's Association Workgroup research criteria for diagnosis and staging of Alzheimer's disease hypothesize diagnostic meaning in the absence of clinical symptoms. If operationalized, this would trivialize neuropsychological assessment but would also expand the pool of candidates for anti-amyloid therapies. A recent survey of the reactions of clinical neuropsychologists to these criteria suggested that the purpose lacked clarity, among other concerns. Given the current landscape in Alzheimer's disease therapeutics, with substantial toxicity and unclear benefit, as well as the poorly understood relationships between biomarkers and clinical signs at the individual level, the roll out of biomarker-only disease seems premature.
Year:
2025
Severe pneumonia is associated with an increased risk of cognitive decline and dementia, particularly in the elderly. Changes in microglia, the most abundant immune cell population in the brain, are also associated with cognitive decline and dementia, including the emergence of a transcriptional cell state referred to as disease-associated microglia (DAM). We sought to test the hypothesis that non-neuroinvasive influenza A virus (IAV) pneumonia results in transcriptional responses in brain microglia that drive premature expansion of DAM. Using bulk and single-cell RNA-sequencing, metabolomics, and spatial transcriptomics, we profiled neuroimmune populations in young, middle-aged, and old male mice during IAV infection and recovery. We observed an increased abundance of DAM, interferon-responsive microglia (IRM), CD4+ T cells, and CD8+ T cells in white matter regions beginning in middle age and persisting in old animals, irrespective of IAV infection. DAM exhibited a metabolic shift toward aerobic glycolysis with disrupted TCA cycling, citrulline depletion, and an elevated itaconate/α-ketoglutarate ratio. Spatial transcriptomic profiling of the human middle frontal gyrus (MFG) in normal agers, SuperAgers, and patients with dementia revealed an analogous accumulation of DAM and CD8+ T cells in white matter. IAV pneumonia induced a transient immunosenescent-like response in microglia, marked by glucocorticoid-responsive gene expression and Ccnd3 upregulation. In response to IAV pneumonia, DAM expanded in middle-aged mice, whereas old mice were elevated at baseline and were largely unaffected by IAV infection. The age-related expansion of DAM was unaffected by pharmacological depletion and repopulation of microglia with a CSF1R antagonist or genetic gain or loss of function of the phagocytic receptor MERTK, suggesting the DAM phenotype is driven by the CNS microenvironment, rather than cell-intrinsic mechanisms. Our findings suggest that IAV pneumonia induces an acute immunosenescence response in microglia and accelerates the age-dependent expansion of DAM in white matter.
Year:
2025
The amyloid cascade hypothesis for Alzheimer’s disease is still alive, although heavily challenged. Effective anti-amyloid immunotherapy would confirm the hypothesis’ claim that the protein amyloid-beta is the cause of the disease. Two antibodies, aducanumab and lecanemab, have been approved by the U.S. Food and Drug Administration, while a third, donanemab, is under review. The main argument for the FDA approvals is a presumed therapy-induced removal of cerebral amyloid deposits. Lecanemab and donanemab are also thought to cause some statistical delay in the determination of cognitive decline. However, clinical efficacy that is less than with conventional treatment, selection of amyloid-positive trial patients with non-specific amyloid-PET imaging, and uncertain therapy-induced removal of cerebral amyloids in clinical trials cast doubt on this anti-Alzheimer’s antibody therapy and hence on the amyloid hypothesis, calling for a more thorough investigation of the negative impact of this type of therapy on the brain.
Year:
2024
Year:
2024
Year:
2023
Collaborators (9)
Grant Iverson
Professor
Harvard University
Claire Shepherd
University of New South Wales
Alexander Misharin
Associate Professor
Northwestern University Feinberg School of Medicine
Navdeep S. Chandel
Professor
Northwestern University Feinberg School of Medicine
Germán Plascencia-Villa
Associate Professor Research
University of Texas at San Antonio
GR Scott Budinger
Professor of Medicine
Northwestern University
Tamar Gefen
Associate Professor
Feinberg School of Medicine
Hiam Abdala Valencia
Associate Professor
Northwestern University
George Perry
Professor
University of Texas at San Antonio
Make your next move.
Prepare your application
Review drafts before you send them.